In an interview on CNBC’s Mad Money, Jeff Simmons said Elanco (ELAN) is focused on growth, innovation and cash. The company has the best pharmaceuticals, he noted. It has six blockbusters approved in major markets and it’s taking share, he added. The protein revolution is real and it’s key, according to Simmons. He sees dairy and beef as great growth categories for Elanco.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco price target raised to $30 from $26 at Leerink
- Morning Movers: Intuit climbs following AI agent partnership with Anthropic
- Elanco Animal Health: Innovation-Led Growth and Conservative Guidance Support Buy Rating and Attractive Risk/Reward
- Elanco reports Q4 adjusted EPS 13c, consensus 11c
- Elanco sees FY26 adjusted EPS $1.00-$1.06, consensus $1.03